ALK-Abelló A/S ALK-Abelló A/S

ALK-Abelló A/S

ALK-B

Kedudukan dalam Saham #2354
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Harga Saham
$37.76
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$8.38B
Perubahan (1 hari)
-0.08%
Perubahan (1 tahun)
14.34%
Negara
DK
Perdagangan ALK-Abelló A/S (ALK-B)

Kategori

Healthcare
Sejarah pecahan saham untuk ALK-Abelló A/S (ALK-B)
Saham ALK-Abelló A/S (simbol: ALK-B) telah mengalami sejumlah 1 pecahan saham.
Pecahan saham terkini berlaku pada Mar 28, 2022.
Satu saham ALK-B yang dibeli sebelum Mar 28, 2022 kini bersamaan dengan 20 saham ALK-B.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
2022-03-28 20:1 x20 x20
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL